Yeah MSB had eIND as well, used it to treat twelve patients, started a phase 3 trial and ceased it early due to failure.
Therapeutic solutions already treated 15 patients under eIND, is partway through their phase three trial, and just got further eIND to treat patients outside of the trial.
And this is a direct competitor.
This is not good news for MSB.
Interesting MSC's Article, page-6
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.35 |
Change
0.105(8.43%) |
Mkt cap ! $1.541B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.40 | $1.27 | $16.46M | 12.22M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 59739 | $1.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.36 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |